In 2018, osimertinib showed superior progression-free survival (PFS) and in 2020, improved median OS, compared to first-generation TKIs gefitinib or erlotinib in epidermal growth factor receptor (EGFR) mutation-positive NSCLC [9,10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.